Who Paid My Doc
Ixempra
Drug Oncology
NDC 70020-1910-1
General payments
$86,628
Research payments
$0
Through program year 2024, $86,628 in general payments and $0 in research payments were reported against Ixempra (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $475 | 6 |
| 2022 | General | $141 | 3 |
| 2021 | General | $16 | 1 |
| 2020 | General | $13,575 | 23 |
| 2019 | General | $72,421 | 110 |
Breakdown
The top 5 of 6 recipients; each share is of general payments naming this product in 2024.
Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2024 where a state was reported.
Records
143 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.